Endothelin-1 induces expression of fetal genes through the interleukin-6 family of cytokines in cardiac myocytes  by Saito, Shuichi et al.
Endothelin-1 induces expression of fetal genes through the interleukin-6
family of cytokines in cardiac myocytes
Shuichi Saito, Ryuichi Aikawa, Ichiro Shiojima, Ryozo Nagai, Yoshio Yazaki, Issei Komuro*
Department of Cardiovascular Medicine, University of Tokyo Gradulate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Received 3 June 1999; received in revised form 29 June 1999
Abstract We here examined the role of the interleukin-6 (IL-6)
family of cytokines in endothelin-1 (ET-1)-induced hypertrophic
responses using cultured cardiac myocytes of neonatal rats. ET-1
induced expression of IL-6 and leukemia inhibitory factor (LIF)
genes. ET-1-induced LIF gene expression was abolished by
inhibition of protein kinase C activity. ET-1 activated the
promoter of atrial natriuretic peptide and L-type myosin heavy
chain genes through the tyrosine kinase pathway and IL-6
receptor gp130. These results suggest that the IL-6 family of
cytokines mediates ET-1-induced expression of some fetal genes
in cardiac myocytes.
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1. Introduction
Clinical studies have demonstrated that cardiac hypertro-
phy is not only an adaptational state before cardiac failure,
but also an independent risk factor for cardiac morbidity and
mortality [1]. Thus, it has become even more important to
determine the molecular mechanism of cardiac hypertrophy.
Recent studies have indicated that cardiac hypertrophy is in-
duced by mechanical stress [2] and neurohumoral factors such
as angiotensin II (Ang II) [3], endothelin-1 (ET-1) [4], phenyl-
ephrine [5] and the interleukin-6 (IL-6) family of cytokines
[6,7] in cardiac myocytes.
ET-1 has been reported to be not only a vasoconstrictor,
but also a potent hypertrophy-promoting factor in a variety of
mammalian cells including vascular smooth muscle cells [8],
cardiomyocytes [9] and ¢broblasts [10]. We have reported that
mechanical stress induces hypertrophic responses such as ac-
tivation of mitogen-activated protein kinase (MAPK) and
Raf-1 kinases, expression of speci¢c genes and an increase
in protein synthesis in cardiac myocytes partly through ETA
receptors [4]. Furthermore, it has been shown that ET-1 in-
duces expression of proto-oncogenes [9,11], the brain natriu-
retic peptide (BNP) gene [12] and muscle speci¢c genes such as
myosin light chain 2, skeletal K-actin and troponin I [9]. These
results suggest that ET-1 is produced from cardiomyocytes
and plays an important role in the development of cardiac
hypertrophy including induction of fetal genes. However, it
remains to be determined how ET-1 induces fetal gene expres-
sion in cardiomyocytes.
The IL-6 family of cytokines, including IL-6, IL-11, leuke-
mia inhibitory factor (LIF), cardiotrophin-1 (CT-1) and cili-
ary neurotrophic factor, has been reported to induce cardio-
myocyte hypertrophy through gp130, a common L-receptor
[13]. These IL-6-related cytokines activate Janus kinase
(JAK), which evokes two signaling pathways, MAPK and
signal transducer and activator of transcription (STAT) [13].
Furthermore, it has been shown that the IL-6 family of cyto-
kines induces expression of c-fos and atrial natriuretic peptide
(ANP) genes, followed by an increase in protein synthesis in
cardiomyocytes [6,14].
To elucidate the relation between ET-1 and the IL-6 family
of cytokines, we here examined the possibility that the IL-6
family of cytokines is involved in ET-1-induced expression of
fetal genes in cultured cardiomyocytes of neonatal rats.
2. Materials and methods
2.1. Cell culture
Primary cultures of cardiac myocytes were prepared from the ven-
tricles of 1 day old Wistar rats as described previously [2]. Cells were
plated onto plastic culture dishes at a ¢eld density of 1U105 cells/cm2.
2.2. RNA isolation and reverse transcription followed by polymerase
chain reaction (RT-PCR) analysis
Total RNA was extracted from cardiac myocytes by using RNA
STAT-60 (TEL-TEST B) according to the manufacturer’s instruc-
tions. RNA was treated with DNAse to eliminate any contamination
of genomic DNA. Rat IL-6, LIF, CT-1 and GAPDH mRNA were
ampli¢ed by PCR using the following primers.
Rat IL-6, 5P-GACTGATGTTGTTGACAGCCACTGC-3P for
sense and 5P-TAGCCACTCCTTCTGTGACTCTAACT-3P for anti-
sense; rat LIF, 5P-AGTCAACTGGCTCAACTCAACG-3P for sense
and 5P-CTGGGCCAACACACTTATGACT-3P for antisense; rat CT-
1, 5P-GAGACCGTGCTGGCCGCTCTGG-3P for sense and 5P-GG-
CGAGAGCAGAAGAAGAAAGAG-3P for antisense; rat GAPDH,
5P-CCATGGAGAAGGCTGGGG-3P for sense and 5P-CAAAGTT-
GTCATGGATGACC-3P for antisense. The predicted sizes of the
PCR-ampli¢ed products were 509 bp for IL-6, 441 bp for LIF, 188
bp for CT-1 and 175 bp for GAPDH. PCR was performed with a
DNA Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT, USA) us-
ing various cycles. After ampli¢cation, products were analyzed by
electrophoresis on a 2^3% agarose gel.
2.3. Transfection and reporter gene assay
0.5 Wg of reporter plasmid with or without 1 ng of dominant neg-
ative mutant of gp130 plasmid (D.N. gp130, kindly provided by Dr T.
Taga) [15] were transfected into cardiac myocytes cultured in a 35 mm
dish. The cells were washed with PBS at 6 h after transfection and
incubated with serum free DMEM for 24 h. Cells were then stimu-
lated by ET-1 (1037 M) or LIF (103 U/ml) and incubated for 48 h.
The luciferase activities were measured by a luminometer (Lumino-
scan, Labsystems). All transfection experiments were performed three
times.
2.4. Statistical analysis
All results are expressed as mean þ S.E.M. Multiple comparisons
among three groups were carried out by two-way ANOVA and Fish-
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er’s exact test for post hoc analyses. A value of P6 0.05 was consid-
ered statistically signi¢cant.
3. Results
3.1. ET-1 induces expression of IL-6-related cytokine genes in
cardiomyocytes
Since it has been reported that ET-1 regulates synthesis of
IL-6 under in£ammations in endothelial cells [16], bronchial
epithelial cells [17] and leukocytes [18], we examined whether
ET-1 induces expression of IL-6-related cytokine genes in car-
diac myocytes by RT-PCR. Untreated cardiac myocytes did
not express any IL-6-related cytokines. When ET-1 (1037 M)
was added to cultured cardiac myocytes, mRNA levels of IL-6
and LIF began to increase from 30 min and peaked at 60 min.
The mRNA levels were decreased thereafter, but were still
signi¢cantly higher than control levels at 120 min. ET-1 did
not increase expression levels of the CT-1 gene in cardiac
myocytes (Fig. 1).
3.2. ET-1-induced expression of IL-6-related cytokine genes is
mediated by the PKC-dependent pathway
It has been reported that ET-1 activates phospholipase C,
which causes protein kinase C (PKC) and an increase in Ca2
in many cell types including cardiac myocytes [4,10]. Since
activated PKC induces hypertrophic responses such as an in-
crease in protein synthesis and reprogramming of gene expres-
sions in cardiac myocytes [2,19], we examined whether ET-1
upregulates expression of IL-6-related cytokine genes through
the PKC-dependent pathway in cardiac myocytes. 12-O-tetra-
decanoylphorbol-13-acetate (TPA) (1036 M) induced expres-
sion of the LIF gene by almost the same levels as with ET-1
(Fig. 2). ET-1-induced LIF gene expression was completely
inhibited by pretreament with a PKC inhibitor, calphostin C
(5U1036 M) for 60 min or with TPA (1037 M) for 24 h [19]
(Fig. 2). We next examined the role of Ca2 in expression of
IL-6-related cytokine genes. Incubation with a Ca2 iono-
phore, ionomycin (1036 M), for 60 min, induced expression
of IL-6 and LIF mRNA (Fig. 3). Although expression of CT-
1 was observed in unstimulated control cells, expression levels
of the CT-1 gene were not changed by ionomycin as well as
ET-1 (data not shown). To examine whether Ca2 is critically
involved in ET-1-induced expression of IL-6-related cytokine
genes, we pretreated cardiac myocytes with a calmodulin in-
hibitor, W-7 (1035 M) [20], a Ca2/calmodulin-dependent pro-
tein (CaM) kinase II inhibitor, KN-93 (3U1035 M) [21], a
calcineurin inhibitor, cyclosporin A (5U1036 M) [22], and
extracellular Ca2 chelator, EGTA (5U1033 M). ET-1-in-
duced expression of the LIF gene was not a¡ected by these
inhibitors except EGTA (Fig. 3), suggesting that PKC but not
Ca2 plays an important role in ET-1-induced expression of
the LIF gene.
3.3. ET-1 activates ANP and L-type myosin heavy chain
(L-MHC) promoters through tyrosine kinases
The hypertrophic responses in cardiac myocytes are char-
acterized by the induction of a fetal gene program [23]. It has
been reported that ET-1 and CT-1 induce expressions of fetal
genes such as ANP and skeletal K-actin through PKC activa-
tion [9] and tyrosine kinases [6], respectively. To get insight
into the relation between ET-1- and IL-6-related cytokines, we
examined whether tyrosine kinases are also involved in ET-1-
Fig. 1. E¡ects of ET-1 on IL-6, LIF and CT-1 gene expression in
neonatal rat cardiomyocytes. Cells were incubated with ET-1 (1037
M) for the indicated times. DNA ampli¢ed by RT-PCR was electro-
phoresed on 2^3% agarose gels and stained with ethidium bromide.
GAPDH was also ampli¢ed from the same cDNA to show that
equal amounts of cDNA were used in each lane.
Fig. 2. The role of PKC in ET-1-induced LIF gene expression in
cardiomyocytes. Cells were pretreated with calphostin C (5U1036
M) for 30 min or TPA (1037 M) for 24 h and stimulated by ET-1
or TPA. RT-PCR was performed and ampli¢ed DNA was subjected
to gel electrophoresis. Lanes: 1, control; 2, ET-1 (1037 M); 3, TPA
(1036 M); 4, ET-1 plus calphostin C (5U1036 M) pretreatment for
30 min; 5, ET-1 plus TPA (1037 M) pretreatment for 24 h.
Fig. 3. The role of Ca2 in ET-1-stimulated LIF gene expression.
Cells were pre-incubated with W-7 (1035 M), KN-93 (3U1035 M),
cyclosporin A (5U1036 M) for 1^3 h or EGTA (5U1033 M) for 1
min and stimulated by ET-1 or ionomycin for 60 min. RT-PCR
was performed and ampli¢ed DNA was subjected to gel electropho-
resis. Lanes: 1, control; 2, ET-1 (1037 M); 3, ionomycin (1036 M);
4, ET-1 plus W-7 (1035 M) pretreatment; 5, ET-1 plus KN-93
(3U1035 M) pretreatment; 6, ET-1 plus cyclosporin A (5U1036 M)
pretreatment; 7, ET-1 plus KN-93 and cyclosporin A pretreatment;
8, ET-1 plus EGTA (5U1033 M) pretreatment.
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induced expression of cardiac fetal genes. Incubation with
ET-1 (1037 M) for 48 h increased ANP-, BNP- and L-MHC
promoter activities by 11.3-, 6.4- and 4.2-fold as compaired
with control levels, respectively. When cardiac myocytes were
pre-incubated with a tyrosine kinase inhibitor, genistein
(5U1036 M) for 60 min, ET-1-induced activation of ANP
and L-MHC genes was signi¢cantly suppressed. However, pre-
treatment with genistein did not a¡ect the promoter activity of
the BNP gene enhanced by ET-1 (Fig. 4A).
3.4. Overexpression of the dominant negative mutant of gp130
inhibits ANP and L-MHC promoter activation induced by
ET-1
To clarify whether IL-6-related cytokines are involved in
ET-1-induced fetal gene expressions, we transfected a domi-
nant negative mutant of gp130 (D.N. gp130) with fetal gene
promoters into cardiac myocytes. The transfection e⁄ciency
of luciferase reporter genes was not changed with or without
D.N. gp130 (data not shown). ANP- and L-MHC-luciferase
activities enhanced by ET-1 (1037 M) were strongly inhibited
by overexpression of D.N. gp130. In contrast, ET-1-induced
activation of BNP and elongation factor (EF) promoters were
not a¡ected by overexpression of D.N. gp130 (Fig. 4B). These
results indicate that gp130 is critically involved in ET-1-in-
duced reprogramming of ANP and L-MHC gene expression
in cardiac myocytes.
3.5. LIF activates ANP, BNP and L-MHC promoters
It has been reported that gp130 activation by exposure to
LIF or CT-1 causes induction of ANP expression in cardiac
myocytes [6,14]. Therefore, we ¢nally examined whether LIF
activates the promoter of BNP and L-MHC genes in cardiac
myocytes. LIF (103 U/ml) increased for 48 h ANP, BNP and
L-MHC luciferase activities by approximately 9.6-, 5.0- and
2.8-fold as compared with control levels, respectively (Fig. 5).
These results indicate that LIF induces expression of BNP
and L-MHC genes as well as the ANP gene in cardiac myo-
cytes.
4. Discussion
A variety of growth and neurohumoral factors such as Ang
Fig. 4. The roles of tyrosine kinases and gp130 in ET-1-induced activation of ANP, BNP and L-MHC promoters. (A) Cells transfected with
ANP, BNP or L-MHC promoter/luciferase reporter gene were stimulated by ET-1 (1037 M) for 48 h with or without pretreatment of genistein
(5U1034 M) for 30 min. (B) ANP, L-MHC, BNP or EF promoter/luciferase was transfected into cardiomyocytes with or without the D.N.
gp130 gene and then, cells were stimulated by ET-1 (1037 M) for 48 h. Luciferase activity was normalized to Renilla luciferase activity for each
sample and expressed as the fold increase relative to no drug treatment ( = 100). Data show the mean þ S.E.M. of three independent assays.
*, P6 0.05 versus control. **, P6 0.05 versus ET-1 treatment without D.N. gp130.
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II [19], ET-1 [4] and K1-adrenergic agonist [5] have been re-
ported to induce hypertrophic responses in cardiomyocytes.
Recently, ET-1 has been reported to induce expression of
IL-6 and LIF genes in rat endothelial cells [16] and mesangial
cells [24] through an increase in intracellular Ca2 levels. In
the present study, ET-1 induced expression of IL-6 and LIF
genes in cardiac myocytes. ET-1-induced LIF gene expression
was completely suppressed by inhibition or down-regulation
of PKC activity and TPA upregulated mRNA levels of IL-6
and LIF. Although ionomycin also induced expression of IL-6
and LIF genes, inhibition of calmodulin, CaM kinase II and
calcineurin had no e¡ect on expression of LIF mRNA by
ET-1. These results suggest that PKC activation is important
for ET-1-induced LIF mRNA expression in cardiac myocytes.
Since some isoforms of PKC are activated in response to an
increase in intracellular Ca2 [25], ionomycin may induce ex-
pression of these cytokines through activation of PKC and
ET-1-induced LIF gene expression may be inhibited by
EGTA in cardiac myocytes. Further studies are required to
elucidate which isoform of PKC is involved in ET-1-induced
expression of these cytokines. CT-1 is also a member of the
IL-6 cytokine family and has a wide range of growth and
di¡erentiation activities on many cell types including cardiac
myocytes [6]. The present study demonstrated that although
CT-1 was expressed in untreated cardiomyocytes, stimulation
with ET-1 or ionomycin did not enhance mRNA levels of
CT-1. Recently, it has been reported that the 5P-£anking re-
gion of the human CT-1 gene is isolated [26]. The regulatory
mechanism of CT-1 may be di¡erent from that of IL-6 and
LIF.
It has recently been reported that activation of tyrosine
kinases increases expression of ANP, L-MHC and skeletal
K-actin genes in rat cardiomyocytes [27] and that ET-1 rapidly
enhances tyrosine phosphorylation in mesangial cells or vas-
cular smooth muscle cells. We examined the possibillity that
activation of tyrosine kinase is involved in ET-1-induced fetal
gene expression. When cardiomyocytes were pretreated with a
tyrosine kinase inhibitor, ET-1-induced expression of ANP
and L-MHC genes, but not the BNP gene, was strongly re-
duced. Since ET-1 directly activates PKC but not tyrosine
kinases in cardiac myocytes, we speculate that ET-1 induces
the fetal gene program through other factors which activate
tyrosine kinases.
It has been reported that IL-6-related cytokines activate the
tyrosine kinase JAK through gp130 in cardiomyocytes [7].
Overexpression of D.N. gp130 markedly suppressed ET-1-in-
duced activation of ANP and L-MHC promoter in cardiac
myocytes and LIF activated promoters of ANP, BNP and
L-MHC genes. Taken together, IL-6-related cytokines induced
by ET-1 may activate tyrosine kinases through gp130, leading
to activation of the fetal gene program during cardiac hyper-
trophy. However, ET-1-induced activation of the BNP pro-
moter gene was not inhibited by either a tyrosine kinase in-
hibitor or overexpression of D.N. gp130. It has been reported
that transcription of the BNP gene is rapidly increased in
response to hemodynamic overload following heart failure
and myocardial infarction [28]. ET-1 also rapidly increases
expression levels of the BNP gene within 60 min in cultured
rat cardiomyocytes [12], indicating that the BNP gene is one
of the immediate early response genes. Furthermore, it has
been reported that the ET-1-induced BNP gene expression is
signi¢cantly suppressed by PKC inhibitors [12]. This result
suggests that PKC activation is one of the proximal signaling
pathways in the rapid induction of the BNP gene expression.
Therefore, it is possible that ET-1 may induce expression of
cardiac speci¢c genes through two di¡erent pathways, one
pathway depends on IL-6-related cytokines and the other
pathway is directly activated by ET-1 in cardiac myocytes.
In summary, these studies suggest that IL-6-related cyto-
kines are induced by ET-1 through the PKC pathway in car-
diac myocytes and that ET-1-induced activation of the fetal
gene program is mediated by the cytokines. It remains to be
determined how these cytokines induce expression of fetal
genes.
Fig. 5. E¡ect of LIF on ANP, BNP and L-MHC promoters. Cells
were transfected with ANP, BNP, or L-MHC promoter/luciferase re-
porter gene and then stimulated by LIF (103 U/ml) for 48 h. Data
show the mean þ S.E.M. of three independent assays. *, P6 0.05
versus control.
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